Mark Avagliano G1 Therapeutics, Inc. (GTHX) insider trading activity

Mark Avagliano is Chief Business Officer of G1 Therapeutics, Inc.. Currently has a direct ownership of 0 shares of GTHX, which is worth approximately $0. The most recent transaction as insider was on Sep 18, 2024, when has been sold 236,610 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

100.0% 12M change

Total Value Held $0

Mark Avagliano Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 18 2024	SELL Sale (or disposition) back to the issuer	-	236,610 Reduced 90.09%	26,035 Common Stock
Sep 18 2024	SELL Disposition due to a tender of shares in a change of control transaction	-	26,035 Reduced 100.0%	0 Common Stock
Sep 18 2024	BUY Grant, award, or other acquisition	-	20,600 Added 7.27%	262,645 Common Stock
Jul 05 2024	SELL Open market or private sale	$6,621 $2.51 p/Share	2,638 Reduced 1.08%	242,045 Common Stock
Jul 01 2024	BUY Grant, award, or other acquisition	-	35,000 Added 12.51%	244,683 Common Stock
May 13 2024	SELL Open market or private sale	$39,043 $4.79 p/Share	8,151 Reduced 3.74%	209,683 Common Stock
Mar 20 2024	BUY Grant, award, or other acquisition	-	100,000 Added 31.46%	217,834 Common Stock
Jan 04 2024	SELL Open market or private sale	$2,119 $2.94 p/Share	721 Reduced 0.61%	117,834 Common Stock
Jan 03 2024	SELL Open market or private sale	$10,483 $3.12 p/Share	3,360 Reduced 2.76%	118,555 Common Stock
Jan 03 2024	BUY Grant, award, or other acquisition	-	44,760 Added 26.85%	121,915 Common Stock
May 10 2023	BUY Grant, award, or other acquisition	-	35,000 Added 31.21%	77,155 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	20,600 Added 32.83%	42,155 Common Stock
Jan 05 2022	SELL Open market or private sale	$15,331 $10.61 p/Share	1,445 Reduced 6.28%	21,555 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	12,000 Added 34.29%	23,000 Common Stock
Jan 04 2021	BUY Grant, award, or other acquisition	-	11,000 Added 50.0%	11,000 Common Stock

Mark Avagliano

Chief Business Officer

Research Triangle Park, NC

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GTHX shares.

Notify only if

Value

Insider Trading

Get notified when an G1 Therapeutics, Inc. insider buys or sells GTHX shares.

Notify only if

Operation

Value

Type

News

Receive news related to G1 Therapeutics, Inc.

Track Activities on GTHX

Account